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Nijmegen, The Netherlands; dDepartment of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands
ABSTRACT
Background Diarrhea is a frequently occurring adverse event during treatment with vascular
endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and is mostly
accompanied by abdominal cramps, flatulence and pyrosis. These complaints impair quality of
life and lead to dose reductions and treatment interruptions. It is hypothesized that the diarrhea
might be due to ischemia in bowel mucosa or inflammation, but the exact underlying
pathophysiological mechanism of the diarrhea is still unknown. We aimed at exploring the
mechanism for diarrhea in these patients by thorough endoscopic and histological assessment.
Materials and methods Endoscopies of the upper and lower gastrointestinal (GI) tract in 10
patients with metastatic renal cell carcinoma (mRCC) who developed diarrhea during treatment
with VEGFR TKIs were performed.
Results Ten patients were included. The results showed endoscopically normal mucosa in the
lower GI tract in seven patients without signs of ischemic colitis or inflammation.
Gastroduodenoscopy revealed gastro-esophageal reflux disease, bulbitis and/or duodenitis with
ulcers in eight patients. In three selected patients with bulbitis/duodenitis additional video capsule
endoscopy was performed but revealed no additional intestinal abnormalities.
Conclusion We observed frequent mucosal abnormalities in the upper GI tract in VEGFR TKI-
treated mRCC patients with diarrhea. Although these abnormalities provide insufficient explanation
for the occurrence of diarrhea, we suggest to perform routine upper GI endoscopy in VEGFR TKI-
treated patients with GI complaints.
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Tyrosine kinase inhibitors (TKIs) of the vascular endothelial
growth factor receptors (VEGFR), such as sunitinib, sorafenib
and pazopanib, have improved survival in patients with
metastatic renal cell carcinoma (mRCC). These drugs showed
to increase progression-free survival and stabilization of the
disease compared to interferon alpha [1,2] or placebo [3,4].
VEGFR TKIs inhibit angiogenesis, cell proliferation and tumor
cell invasion. In general, VEGFR TKIs are tolerated reasonably
well, but diarrhea is a frequently reported side effect [1,3–7]
which may persist for a prolonged period of time. In 53% of
375 patients treated with sunitinib diarrhea was observed and
in 5% of cases it was severe, defined as grade 3 diarrhea
according to the common terminology criteria for adverse
events (CTCAE) [1]. A phase III study with pazopanib reported
similar percentages, 52% of patients having diarrhea which was
severe diarrhea in 4% [4].
Diarrhea negatively influences the quality of life due to
flatulence, cramps, urge and fecal incontinence. Furthermore,
diarrhea can necessitate dose reductions or interruptions,
potentially leading to less effectiveness of treatment.
Therefore, it is of utmost importance to understand, treat
and if possible prevent VEGFR TKI-induced diarrhea.
Despite its frequent occurrence, the etiology and patho-
physiological mechanisms that lead to diarrhea in patients
treated with VEGFR TKIs have not been clarified yet. Several
potential causes for diarrhea in these patients have been
previously suggested. VEGFR TKIs do not exclusively inhibit the
vasculature of tumors, but also have their effect on the blood
supply of healthy organs. Cases have been published in which
ischemic colitis and perforation have been reported after
treatment with bevacizumab and VEGFR TKIs [8–12]. Chronic
low-grade ischemia can also occur and lead to chronic
symptoms. We hypothesized that ischemic conditions in the
bowel mucosa might lead to the diarrhea in patients treated
with VEGFR TKIs. Second, it is known that angiogenesis is
involved in the pathogenesis of inflammatory bowel diseases
[13,14]. It may be that inflammation has a role in the
pathogenesis of the diarrhea.
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In order to explore possible causes of diarrhea in patients
who developed diarrhea during treatment with a VEGFR TKI,
including intestinal ischemia and mucosal inflammation, we
performed an endoscopy of the upper and lower gastro-
intestinal (GI) tract.
Material and methods
Ten consecutive patients on VEGFR TKI treatment for mRCC
who developed diarrhea of any grade according to the CTCAE
[15] were asked for participation in this study. Diarrhea was
defined as the sudden deviation of normal bowel movements,
with a higher frequency of bowel movements (at least three
times a day), a larger quantity and feces containing more water
than before. Patients with a known history of bowel diseases,
such as inflammatory bowel disease, lactose intolerance or
celiac disease, were excluded. Patients using laxatives on a
regular basis were also excluded.
The medical ethical committee of our institute (no. 2011/
151) approved this study. After providing written informed
consent, a thorough history was taken, covering all aspects of
diarrhea and accompanying GI complaints in relation to
treatment with the VEGFR TKI. In all patients, both a
sigmoidoscopy and gastroduodenoscopy were performed. At
least two biopsies from stomach, duodenum and sigmoid each
were taken on formalin and liquid nitrogen and stored at -20C
until analysis. In case of macroscopic abnormalities targeted
additional biopsies were taken. A pathologist with expertise in
GI diseases (IN) assessed all biopsies in a systematic way. In the
context of the ‘‘ischemic’’ hypothesis, additional immunohis-
tochemical stainings on stomach, duodenal and sigmoid
biopsies for CD31 (marker for endothelial cells), D2-40
(marker for lymphatic endothelial cells) and VEGFR2 (the
receptor that mediates almost all of the known cellular
responses to VEGF) were done. Stainings for cytomegalovirus
(CMV) and Helicobacter pylori were performed to rule out an
infectious cause.
Results
Patients
Ten patients with metastatic clear cell RCC were enrolled
between November 2011 and March 2013. Patient character-
istics are described in Table I. Nine patients were treated before
study entry with sunitinib for a median duration of 11 months.
One patient was on treatment with cediranib 30mg once daily
in a phase I study since 62 months. The median duration of
therapy before occurrence of the diarrhea was five months
(range 1–14 months), including four patients complaining of
diarrhea since the first cycle. Patients complained about
frequent bowel movements, median 4–5 times a day, typically
starting in the late afternoon or early after dinner and occurring
within a short time interval, e.g. two or three times within 30
minutes (Table II). Seven patients also reported nocturnal
bowel movements necessitating passing stools at night. Five
patients reported fecal incontinence. In eight patients, the
diarrhea was accompanied with abdominal cramps and/or
flatulence. Patients did not report undigested food, blood or
mucus in the stools, nor did they describe the typical findings
of steatorrhoe (pale, greasy, voluminous stools). Seven patients
used loperamide chronically to control their complaints. All
patients changed their food and drinking habits in an attempt
to diminish the complaints: milk products, fat and spicy food
were banned from the menu, with variable results.
Endoscopy: Macroscopic findings
In half of the patients the sigmoidoscopy showed macroscopic
abnormalities with swollen mucosa, a polyp in the rectum,
impression from outside accompanied by an ulcer, teleangiec-
tasias and diverticulosis all occurring once (Table III). With
gastroduodenoscopy macroscopic abnormalities were found in
eight of 10 patients (Table III). Five patients had gastro-
esophageal reflux disease (GERD) and four patients had
endoscopic signs of bulbitis/duodenitis with ulcers. In one
patient with a long history of heartburns and a family history of
reflux esophagitis, a carcinoma in situ of the esophagus was
found, which was treated subsequently by endoscopic mucosal
resection.
Endoscopy: Microscopic findings
The microscopic findings of the biopsies in patients by
sigmoidoscopy and gastroduodenoscopy are shown in
Table III. Biopsies of the sigmoid showed abnormalities in
three patients: a hyperplastic polyp, localization of RCC in the
submucosa/lamina propria and aspecific abnormalities in
architecture with focal bleeding. In three patients the staining
for VEGFR2 showed an increase of VEGFR2 in the epithelium
and subepithelium of the sigmoid.
In biopsies of stomach and duodenum, six cases of chronic
inflammation were found (60%), three cases of active
inflammation, intestinal metaplasia and angiodysplasia (30%)
and two cases of proton pump inhibitor effect, reactive
gastropathy and infection with H. pylori each (20%). Stainings
for CMV, D2-40 and CD31 were normal in all patients.
Additional tests
When we found the mucosal abnormalities such as ulcers
and erosions, in the duodenum and bulbus of four patients,
we hypothesized that this might explain the diarrhea
and subsequently, three patients underwent a video
capsule endoscopy (VCE) in order to assess the entire small
intestine.
In two patients small angiodysplasias, superficial erosive
lesions and microscopic hemorrhages were observed in the
entire small intestine. In one patient the lesions were mostly
localized in the most distal part of the small intestine and also
in the right-sided colon. No ulcers were observed. In the last
patient only very few superficial erosions were seen.
Discussion
Diarrhea is a frequently occurring adverse event of treatment
with VEGFR TKI, which could lead to dose interruptions or
reductions and diminish quality of life. The endoscopies
performed in our study showed no definitive evidence for
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ischemia or inflammation as the cause of the diarrhea.
Unexpectedly, we found focal mucosal abnormalities, such as
erosions and ulcers in esophagus, stomach and duodenum, in
the majority of patients.
Despite the high prevalence of the diarrhea in patients with
VEGFR TKI and the negative consequences on quality of life,
research focusing on the cause of this adverse effect is scarce.
As far as we know, no other cross-sectional studies in which
endoscopy was performed had been published before. Thus
far, only a retrospective case series was published in which
colonoscopy was performed in patients treated with bevaci-
zumab, which showed bowel mucosa changes consistent with
ischemic colitis. However, these patients had severe anal pain
and bowel perforation [8].
The first hypothesis of ischemia is supported by preclinical
research in mice by Kamba et al. [16] which showed that
capillaries of healthy tissue in adult mice regressed in reaction
to anti-VEGF therapy. After anti-VEGF therapy for 2–3 weeks,
20–46% of capillaries in the microvilli in the small intestine
regressed. In our study, neither endoscopic evaluation showed
macroscopic signs of ischemia, nor did (immune)histological
examination. The results of this study also did not give any
indication that inflammation is involved in the pathogenesis of
diarrhea. Biopsies of the sigmoid were almost exclusively
normal as well as the macroscopic pictures were. Histology of
biopsies of the upper GI tract showed signs of focal chronic
and acute inflammation. However, the VCE, performed in
three patients, showed only limited and patchy abnormalities
in the small intestine. As the predominantly occurrence of
abnormalities is in the upper GI tract, this is not a plausible
explanation for the diarrhea.
A study performed by Mir et al. did show that the diarrhea
and hypophosphatemia which developed in eight patients
treated with sorafenib was due to a pancreatic exocrine
dysfunction [17]. Pancreatic exocrine dysfunction leads to
malabsorption, as well as other disorders, such as celiac
disease, lactose intolerance and short bowel syndrome. A
malabsorption syndrome could explain the macrocytosis,
vitamin B12 deficit [18,19] and weight loss despite a normal
caloric intake which often develops in patients who are treated
with VEGFR TKIs. As a result of the nature of this study, we were
not able to investigate non-mucosal diseases, such as
pancreatic exocrine dysfunction. This should be the scope of
new studies.
In this study, five of 10 patients showed signs of GERD. In
addition, one patient was diagnosed with a carcinoma in situ of
the esophagus. Three patients used acetylsalicylic acid (ASA),
which is a known risk factor for the development of gastric and
esophageal mucosal injury [20]. However, two of these patients
also used a proton pump inhibitor in combination with ASA to
protect their mucosa for the detrimental effects. In this study,
seven patients had a body mass index (BMI) above 25 (see
Table I) and were thus overweight, which is also a known risk
factor for GERD. However, one of the patients with a healthy
weight suffered from GERD, whereas the patient with very
severe obesity did not have any abnormalities. Four of the five
patients with GERD were symptomatic and complained of
pyrosis, which started since the initiation of treatment with the
VEGFR TKI. Due to the non-prospective nature of our study, a
causal relationship between the reflux disease and the use of
VEGFR TKI could not be evaluated.
In conclusion, this study did not support an ischemic or
inflammatory cause as the underlying pathophysiological
mechanism for diarrhea in patients treated with VEGFR TKIs.
However, as an unexpected result, we found mucosal
abnormalities, such as erosions and ulcers in esophagus,
stomach and duodenum, in the majority of patients. Based
on these results, we recommend routine gastroduodenoscopy
in patients treated with VEGFR TKIs who report gastrointestinal
symptoms, in order to timely diagnose and treat these
abnormalities.
Table I. Patient characteristics.
Pt no. TKI Dosage (per day)
Age
(year) Sex BMI
Months on
treatment
Start of
diarrhea (months
on treatment) Concomitant medication
1 Sunitinib 37.5 mg CDD 63 M 26.4 12 7 Amlodipine, loperamide
2 Sunitinib 37.5 mg CDD 59 F 24.1 36 3 Atenolol, levothyroxine, loperamide
3 Sunitinib 50 mg 4/2 47 M 26.4 17 7 Amlodipine, atenolol, lisinopril, loperamide, omeprazole
4 Sunitinib 37.5 mg CDD 58 M 23.9 11 7 Amlodipine, levothyroxine, lisinopril, loperamide, pantoprazole
5 Cediranib 30 mg CDD 66 M 25.0 62 14 Amlodipine, doxycyclin, levothyroxine, loperamide
6 Sunitinib 50 mg 4/2 61 M 27.4 7 1 Amlodipine, ASA, hydrochlorothiazide
7 Sunitinib 25 mg CDD 60 M 43.7 10 1 Amlodipine, atenolol
8 Sunitinib 37.5 mg CDD 65 M 28.1 10 7 ASA, furosemide, isosorbide mononitrate, lisinopril, loperamide,
metformin, nebivolol, oxycodone, pantoprazole, simvastatin
9 Sunitinib 37.5 mg 4/2 61 M 28.1 26 1 ASA, atorvastatin, chlortalidone, clopidogrel, diazepam, isosorbide
mononitrate, loperamide, losartan, metoprolol, pantoprazole
10 Sunitinib 37.5 mg CDD 50 M 25.7 9 1 None
ASA, acetylsalicylic acid; BMI, body mass index; CDD, continuous daily dosing; F, female; 4/2, four weeks on two weeks off; M, male; pt no., patient number; TKI,
tyrosine kinase inhibitor.
Table II. Patients’ complaints of diarrhea and other gastrointestinal adverse
events.
Patient
Frequency
per day
Diarrhea
during
the night Cramps Flatulence Pyrosis
1 4–5 Y N Y N
2 5–6 Y N Y N
3 4 Y Y Y Y
4 5–6 Y Y N Y
5 3–4 N N Y N
6 4 N N N Y
7 2–4 N N N N
8 5–6 Y Y Y Y
9 47 Y Y Y Y
10 3 Y Y Y Y
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